Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Issue 6 (December 2018)

• Record Type: Journal Article
• Authors: Lin, Swan; Nikanjam, Mina; Capparelli, Edmund V.; Allegrini, Alessandro; Pavone, Daniele; Yim, Dong-Seok; Hammami, Muhammad M.; Bertino, Joseph S.; Nafziger, Anne N.; Park, Yoo-Sin; Yin, Ophelia Q.; Ma, Joseph D.
• Is Part Of: Therapeutic drug monitoring. Volume 40:Issue 6(2018:Dec.)
• Publication Date: 2018-12
• Subjects: cytochrome P450 -- omeprazole -- limited sampling strategy -- CYP2C19; Pharmacokinetics -- Periodicals; Patient monitoring -- Periodicals; Drugs -- Analysis -- Periodicals; Body fluids -- Analysis -- Periodicals; Drug Therapy -- Periodicals; Monitoring, Physiologic -- Periodicals; Pharmacology -- Periodicals; 615.7
• DOI: 10.1097/FTD.0000000000000554
• Languages: English
• ISSNs: 0163-4356

Abstract

Abstract : Background: Limited sampling strategy (LSS) is a validated method to estimate pharmacokinetic (PK) parameters from a reduced number of samples. Omeprazole is used to phenotype in vivo cytochrome P450 (CYP) 2C19 activity. This study examined an LSS using 2 estimation methods to determine apparent oral clearance (CL/F) and thus CYP2C19 activity. Methods: Data from 7 previously published studies included healthy subjects receiving a single, oral dose of omeprazole with intensive PK sampling. CL/F was estimated using noncompartmental analysis (NCA) and population PK modeling. LSS was simulated by selecting the 1, 2, 4, and/or 6-hour postdose time points. Linear regression was performed to assess whether CL/F estimated from limited sampling could accurately predict CL/F from the full PK profile. Results: Median CL/F was 23.7 L/h by NCA and 19.3 L/h by population PK modeling. In comparing the LSS NCA estimated versus observed CL/F, all evaluated linear regression models had unacceptable coefficients of determination ( r 2, range: 0.14–0.81). With the population PK approach, 737 plasma concentrations (n = 71) and CYP2C19 genotype data were described with a 1-compartment structural model with mixed zero and first-order absorption and lag time. In comparing the population PK LSS estimated versus observed CL/F, all evaluated linear regression models had unacceptable r 2 (range: 0.02–0.74). Post hoc comparison of CYP2C19 poor metabolizers versus CYP2C19 extensive metabolizers resulted in significantly lower CL/F in poor metabolizers versus extensive metabolizers. Conclusions: Omeprazole LSS performed poorly in estimating CL/F using 2 separate estimation approaches and does not seem to be a suitable method for determining CYP2C19 activity. Abstract : Supplemental Digital Content is Available in the Text.